ACP
AGIO icon

Altitude Crest Partners’s Agios Pharmaceuticals AGIO Stock Holding History

Altitude Crest Partners’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-113,100
Closed -$3.31M – 1
2024
Q1 		$3.31M Buy
+113,100
New +$3.03M 1.42% 21

Other funds holding AGIO

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Altitude Crest Partners's AGIO Position: Q2 2024 in Review

Altitude Crest Partners sold out of Agios Pharmaceuticals (AGIO) in Q2 2024, closing a stake of 113,100 shares — an estimated $3.31M sold.

Altitude Crest Partners first reported a position in AGIO in Q1 2024 and held it in 1 quarter. The position peaked at $3.31M in Q1 2024. 205 funds tracked by Wall St. Rank hold AGIO as of Q2 2024.

  • Altitude Crest Partners reported no remaining Agios Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Altitude Crest Partners sold 113,100 Agios Pharmaceuticals shares in Q2 2024, an estimated $3.31M.
  • Altitude Crest Partners first reported a position in Agios Pharmaceuticals in Q1 2024 and held it in 1 quarter.
  • Altitude Crest Partners's Agios Pharmaceuticals position peaked at $3.31M in Q1 2024.
  • 205 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2024.

Based on Altitude Crest Partners's 13F filing for Q2 2024.